Single User License
INR 129300
Site License
INR 258600
Corporate User License
INR 387900

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Schizophrenia-Pipeline Review, H1 2015

Schizophrenia-Pipeline Review, H1 2015


  • Products Id :- GMDHC6568IDB
  • |
  • Pages: 375
  • |
  • June 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Schizophrenia-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Schizophrenia-Pipeline Review, H1 2015', provides an overview of the Schizophrenia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Schizophrenia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Schizophrenia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 6

Schizophrenia Overview 7

Therapeutics Development 8

Schizophrenia-Therapeutics under Development by Companies 10

Schizophrenia-Therapeutics under Investigation by Universities/Institutes 17

Schizophrenia-Pipeline Products Glance 19

Schizophrenia-Products under Development by Companies 23

Schizophrenia-Products under Investigation by Universities/Institutes 32

Schizophrenia-Companies Involved in Therapeutics Development 33

Schizophrenia-Therapeutics Assessment 111

Drug Profiles 125

Schizophrenia-Recent Pipeline Updates 284

Schizophrenia-Dormant Projects 333

Schizophrenia-Discontinued Products 345

Schizophrenia-Product Development Milestones 350

Appendix 359

List of Tables

Number of Products under Development for Schizophrenia, H1 2015 23

Number of Products under Development for Schizophrenia-Comparative Analysis, H1 2015 24

Number of Products under Development by Companies, H1 2015 26

Number of Products under Development by Companies, H1 2015 (Contd..1) 27

Number of Products under Development by Companies, H1 2015 (Contd..2) 28

Number of Products under Development by Companies, H1 2015 (Contd..3) 29

Number of Products under Development by Companies, H1 2015 (Contd..4) 30

Number of Products under Development by Companies, H1 2015 (Contd..5) 31

Number of Products under Investigation by Universities/Institutes, H1 2015 33

Comparative Analysis by Late Stage Development, H1 2015 34

Comparative Analysis by Clinical Stage Development, H1 2015 35

Comparative Analysis by Early Stage Development, H1 2015 36

Comparative Analysis by Unknown Stage Development, H1 2015 37

Products under Development by Companies, H1 2015 38

Products under Development by Companies, H1 2015 (Contd..1) 39

Products under Development by Companies, H1 2015 (Contd..2) 40

Products under Development by Companies, H1 2015 (Contd..3) 41

Products under Development by Companies, H1 2015 (Contd..4) 42

Products under Development by Companies, H1 2015 (Contd..5) 43

Products under Development by Companies, H1 2015 (Contd..6) 44

Products under Development by Companies, H1 2015 (Contd..7) 45

Products under Development by Companies, H1 2015 (Contd..8) 46

Products under Investigation by Universities/Institutes, H1 2015 47

Schizophrenia-Pipeline by Acadia Pharmaceuticals Inc., H1 2015 48

Schizophrenia-Pipeline by Adamed Sp. z o.o., H1 2015 49

Schizophrenia-Pipeline by Aestus Therapeutics, Inc., H1 2015 50

Schizophrenia-Pipeline by AGY Therapeutics, Inc., H1 2015 51

Schizophrenia-Pipeline by Alkermes Plc, H1 2015 52

Schizophrenia-Pipeline by Amgen Inc., H1 2015 53

Schizophrenia-Pipeline by Angita B.V., H1 2015 54

Schizophrenia-Pipeline by ANP Technologies, Inc., H1 2015 55

Schizophrenia-Pipeline by Ascendis Pharma A/S, H1 2015 56

Schizophrenia-Pipeline by Astellas Pharma Inc., H1 2015 57

Schizophrenia-Pipeline by Athersys, Inc., H1 2015 58

Schizophrenia-Pipeline by BCWorld Pharm Co. Ltd., H1 2015 59

Schizophrenia-Pipeline by BioCrea GmbH, H1 2015 60

Schizophrenia-Pipeline by Biotie Therapies Corp., H1 2015 61

Schizophrenia-Pipeline by Boehringer Ingelheim GmbH, H1 2015 62

Schizophrenia-Pipeline by Cerecor Inc., H1 2015 63

Schizophrenia-Pipeline by Critical Pharmaceuticals Limited, H1 2015 64

Schizophrenia-Pipeline by Curemark, LLC, H1 2015 65

Schizophrenia-Pipeline by Delpor, Inc., H1 2015 66

Schizophrenia-Pipeline by Domain Therapeutics SA, H1 2015 67

Schizophrenia-Pipeline by Dong Wha Pharma Co., Ltd., H1 2015 68

Schizophrenia-Pipeline by Echo Pharmaceuticals B.V., H1 2015 69

Schizophrenia-Pipeline by Egis Gyogyszergyar Nyrt, H1 2015 70

Schizophrenia-Pipeline by Eli Lilly and Company, H1 2015 71

Schizophrenia-Pipeline by Evotec AG, H1 2015 72

Schizophrenia-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 73

Schizophrenia-Pipeline by FORUM Pharmaceuticals Inc., H1 2015 74

Schizophrenia-Pipeline by Galenea Corp., H1 2015 75

Schizophrenia-Pipeline by GeNeuro SA, H1 2015 76

Schizophrenia-Pipeline by Genovate Biotechnology Co., LTD., H1 2015 77

Schizophrenia-Pipeline by Gilead Sciences, Inc., H1 2015 78

Schizophrenia-Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015 79

Schizophrenia-Pipeline by GP Pharm, S.A., H1 2015 80

Schizophrenia-Pipeline by GW Pharmaceuticals Plc, H1 2015 81

Schizophrenia-Pipeline by H. Lundbeck A/S, H1 2015 82

Schizophrenia-Pipeline by Heptares Therapeutics Limited, H1 2015 83

Schizophrenia-Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2015 84

Schizophrenia-Pipeline by Indivior Plc, H1 2015 85

Schizophrenia-Pipeline by INSYS Therapeutics, Inc., H1 2015 86

Schizophrenia-Pipeline by IntelGenx Corp., H1 2015 87

Schizophrenia-Pipeline by Intra-Cellular Therapies, Inc., H1 2015 88

Schizophrenia-Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015 89

Schizophrenia-Pipeline by Jiangsu Nhwa Pharma Corporation, H1 2015 90

Schizophrenia-Pipeline by Johnson & Johnson, H1 2015 91

Schizophrenia-Pipeline by Karuna Pharmaceuticals Inc., H1 2015 92

Schizophrenia-Pipeline by KemPharm, Inc., H1 2015 93

Schizophrenia-Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H1 2015 94

Schizophrenia-Pipeline by Lead Discovery Center GmbH, H1 2015 95

Schizophrenia-Pipeline by Lohocla Research Corporation, H1 2015 96

Schizophrenia-Pipeline by Luye Pharma Group Ltd., H1 2015 97

Schizophrenia-Pipeline by Merck & Co., Inc., H1 2015 98

Schizophrenia-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 99

Schizophrenia-Pipeline by Neurocrine Biosciences, Inc., H1 2015 100

Schizophrenia-Pipeline by NeurOp, Inc, H1 2015 101

Schizophrenia-Pipeline by Newron Pharmaceuticals S.p.A., H1 2015 102

Schizophrenia-Pipeline by Nuvo Research Inc., H1 2015 103

Schizophrenia-Pipeline by Omeros Corporation, H1 2015 104

Schizophrenia-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 105

Schizophrenia-Pipeline by Peptron, Inc., H1 2015 106

Schizophrenia-Pipeline by Pfizer Inc., H1 2015 107

Schizophrenia-Pipeline by Promentis Pharmaceuticals, Inc., H1 2015 108

Schizophrenia-Pipeline by Reviva Pharmaceuticals Inc., H1 2015 109

Schizophrenia-Pipeline by Richter Gedeon Nyrt., H1 2015 110

Schizophrenia-Pipeline by Saniona AB, H1 2015 111

Schizophrenia-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 112

Schizophrenia-Pipeline by SK Chemicals Co., Ltd., H1 2015 113

Schizophrenia-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 114

Schizophrenia-Pipeline by Sunovion Pharmaceuticals Inc., H1 2015 115

Schizophrenia-Pipeline by Suven Life Sciences Ltd., H1 2015 116

Schizophrenia-Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015 117

Schizophrenia-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 118

Schizophrenia-Pipeline by Targacept, Inc., H1 2015 119

Schizophrenia-Pipeline by Tetra Discovery Partners LLC, H1 2015 120

Schizophrenia-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 121

Schizophrenia-Pipeline by Vanda Pharmaceuticals Inc., H1 2015 122

Schizophrenia-Pipeline by XTL Biopharmaceuticals Ltd., H1 2015 123

Schizophrenia-Pipeline by Zogenix, Inc., H1 2015 124

Schizophrenia-Pipeline by Zysis Limited, H1 2015 125

Assessment by Monotherapy Products, H1 2015 126

Assessment by Combination Products, H1 2015 127

Number of Products by Stage and Target, H1 2015 129

Number of Products by Stage and Mechanism of Action, H1 2015 133

Number of Products by Stage and Route of Administration, H1 2015 137

Number of Products by Stage and Molecule Type, H1 2015 139

Schizophrenia Therapeutics-Recent Pipeline Updates, H1 2015 299

Schizophrenia-Dormant Projects, H1 2015 348

Schizophrenia-Dormant Projects (Contd..1), H1 2015 349

Schizophrenia-Dormant Projects (Contd..2), H1 2015 350

Schizophrenia-Dormant Projects (Contd..3), H1 2015 351

Schizophrenia-Dormant Projects (Contd..4), H1 2015 352

Schizophrenia-Dormant Projects (Contd..5), H1 2015 353

Schizophrenia-Dormant Projects (Contd..6), H1 2015 354

Schizophrenia-Dormant Projects (Contd..7), H1 2015 355

Schizophrenia-Dormant Projects (Contd..8), H1 2015 356

Schizophrenia-Dormant Projects (Contd..9), H1 2015 357

Schizophrenia-Dormant Projects (Contd..10), H1 2015 358

Schizophrenia-Dormant Projects (Contd..11), H1 2015 359

Schizophrenia-Discontinued Products, H1 2015 360

Schizophrenia-Discontinued Products (Contd..1), H1 2015 361

Schizophrenia-Discontinued Products (Contd..2), H1 2015 362

Schizophrenia-Discontinued Products (Contd..3), H1 2015 363

Schizophrenia-Discontinued Products (Contd..4), H1 2015 364

List of Figures

Number of Products under Development for Schizophrenia, H1 2015 23

Number of Products under Development for Schizophrenia-Comparative Analysis, H1 2015 24

Number of Products under Development by Companies, H1 2015 25

Number of Products under Investigation by Universities/Institutes, H1 2015 32

Comparative Analysis by Late Stage Development, H1 2015 34

Comparative Analysis by Clinical Stage Development, H1 2015 35

Comparative Analysis by Early Stage Products, H1 2015 36

Assessment by Monotherapy Products, H1 2015 126

Number of Products by Stage and Top 10 Targets, H1 2015 128

Number of Products by Top 10 Mechanism of Actions, H1 2015 132

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 132

Number of Products by Top 10 Routes of Administration, H1 2015 136

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 136

Number of Products by Top 10 Molecule Types, H1 2015 138

Number of Products by Stage and Top 10 Molecule Types, H1 2015 138

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acadia Pharmaceuticals Inc.

Adamed Sp. z o.o.

Aestus Therapeutics, Inc.

AGY Therapeutics, Inc.

Alkermes Plc

Amgen Inc.

Angita B.V.

ANP Technologies, Inc.

Ascendis Pharma A/S

Astellas Pharma Inc.

Athersys, Inc.

BCWorld Pharm Co. Ltd.

BioCrea GmbH

Biotie Therapies Corp.

Boehringer Ingelheim GmbH

Cerecor Inc.

Critical Pharmaceuticals Limited

Curemark, LLC

Delpor, Inc.

Domain Therapeutics SA

Dong Wha Pharma Co., Ltd.

Echo Pharmaceuticals B.V.

Egis Gyogyszergyar Nyrt

Eli Lilly and Company

Evotec AG

F. Hoffmann-La Roche Ltd.

FORUM Pharmaceuticals Inc.

Galenea Corp.

GeNeuro SA

Genovate Biotechnology Co., LTD.

Gilead Sciences, Inc.

Glenmark Pharmaceuticals Ltd.

GP Pharm, S.A.

GW Pharmaceuticals Plc

H. Lundbeck A/S

Heptares Therapeutics Limited

Hisamitsu Pharmaceutical Co., Inc.

Indivior Plc

INSYS Therapeutics, Inc.

IntelGenx Corp.

Intra-Cellular Therapies, Inc.

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Jiangsu Nhwa Pharma Corporation

Johnson & Johnson

Karuna Pharmaceuticals Inc.

KemPharm, Inc.

Laboratorios Farmaceuticos Rovi, S.A.

Lead Discovery Center GmbH

Lohocla Research Corporation

Luye Pharma Group Ltd.

Merck & Co., Inc.

Mitsubishi Tanabe Pharma Corporation

Neurocrine Biosciences, Inc.

NeurOp, Inc

Newron Pharmaceuticals S.p.A.

Nuvo Research Inc.

Omeros Corporation

Otsuka Holdings Co., Ltd.

Peptron, Inc.

Pfizer Inc.

Promentis Pharmaceuticals, Inc.

Reviva Pharmaceuticals Inc.

Richter Gedeon Nyrt.

Saniona AB

SK Biopharmaceuticals Co., Ltd.

SK Chemicals Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Sunovion Pharmaceuticals Inc.

Suven Life Sciences Ltd.

Taisho Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Company Limited

Targacept, Inc.

Tetra Discovery Partners LLC

Teva Pharmaceutical Industries Limited

Vanda Pharmaceuticals Inc.

XTL Biopharmaceuticals Ltd.

Zogenix, Inc.

Zysis Limited

Schizophrenia Therapeutic Products under Development, Key Players in Schizophrenia Therapeutics, Schizophrenia Pipeline Overview, Schizophrenia Pipeline, Schizophrenia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com